Iantrek, Inc. has appointed an ophthalmic industry executive as its new leader: Adam Szaronos.
The move is effective immediately.
Let’s start with a refresher on this company.
Based in White Plains, New York, Iantrek is a biotechnology company specializing in micro- and bio-interventional eye surgery solutions for chronic ocular diseases.
How it’s doing this: By utilizing natural allogeneic biotissues and applying high-precision micro-interventional technology to develop a new bio-intervention surgical category.
- Its portfolio extends to uveoscleral and trabecular minimally-invasive glaucoma surgery (MIGS) devices—but more on that later.
Now to Szaronos.
With nearly 20 years of experience in the pharmaceutical, medical device, and medical technology sectors, Szaraonos is credited with working on 50+ novel tech launches in areas of the ophthalmic space including:
- Cataract surgery
- Refractive surgery
- Vitreoretinal surgery
- Diagnostics
- Digital health
Let’s talk about that experience.
Prior to joining Iantrek, Szaronos served as CEO and president of Trukera Medical (formerly known as TearLab Corporation).
- Under his leadership, the ophthalmic medical diagnostic company rebranded its ScoutPro Osmolarity System and was acquired by Bausch + Lomb in July 2024.
Prior to Trukera: He was with Alcon, holding roles in sales, marketing, and strategic leadership positions within the surgical and vision care businesses.
- His primary responsibilities: Building new business units and bringing technologies to market
So … who is he replacing?
Sean Ianchulev, MD, MPH.
Fun fact: Dr. Ianchulev is actually the founder of Iantrek.
And important to note: He’ll remain with the company as chairman of the Board and chief medical officer.
Nice! So exactly what type of products has the company developed?
Here’s a broad look at Iantrek’s pipeline of those uveoscleral and trabecular devices we mentioned earlier:
- AlloFlo System: Bio-interventional solution for high-precision ab-interno homologous structural reinforcement
- CycloPen System: Designed for high-precision uveoscleral intervention and creation of a controlled cyclodialysis
- C-Rex System: Ergonomically designed for controlled interventional curation of durable cyclodialysis; enables circumferential 180° to 360° excisional goniotomy
- C-Rex Duo: Currently undergoing first-in-human clinical trials
- CanaloFlo: Currently undergoing first-in-human clinical trials
Any notable callouts from these?
AlloFlo and C-Rex—the company’s first two surgical glaucoma devices.
With both currently in the “controlled release stage” in the U.S. market, Iantrek is planning for a full commercial launch later in 2025.
- Along these regulatory lines: The devices also have established reimbursement codes and can be used in combination with cataract surgery or stand-alone, according to the company.
As for recent developments: Last month, the company announced the completion of the first commercial cases in the United States using the C-Rex for canal outflow enhancement in glaucoma surgery.
- For some context on this system: It’s also reported to be the only FDA-registered MIGS tech to perform excisional circumferential trabeculorhexis and dual wall canal intervention.
And prior to this, wasn’t there also data supporting one of Iantrek’s MIGS devices?
Good memory! Backtracking to September 2024, research published in the peer-reviewed Journal of Clinical Medicine reported findings in support of the CycloPen System as a promising advanced surgical technique for open-angle glaucoma (OAG) patients.
See here for our coverage on this.